Selinexor

Generic Name
Selinexor
Brand Names
Xpovio 100 Mg Once Weekly Carton, Nexpovio
Drug Type
Small Molecule
Chemical Formula
C17H11F6N7O
CAS Number
1393477-72-9
Unique Ingredient Identifier
31TZ62FO8F
Background

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...

Indication

Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...

Associated Conditions
Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
Associated Therapies
-
Clinical Trials
Related News

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

First Posted Date
2022-06-16
Last Posted Date
2024-06-17
Lead Sponsor
Li Zhiming
Target Recruit Count
50
Registration Number
NCT05422066
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

and more 3 locations

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

First Posted Date
2022-06-16
Last Posted Date
2024-06-17
Lead Sponsor
Xia Zhongjun
Target Recruit Count
42
Registration Number
NCT05422027
Locations
🇨🇳

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,, Guangzhou, Guangdong, China

🇨🇳

Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

and more 1 locations

Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

First Posted Date
2022-04-19
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
77
Registration Number
NCT05333458
Locations
🇺🇸

Keck Medicine of USC Koreatown, Los Angeles, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 6 locations

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

First Posted Date
2022-04-11
Last Posted Date
2023-02-09
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
20
Registration Number
NCT05322330
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

First Posted Date
2022-03-04
Last Posted Date
2024-04-09
Lead Sponsor
Antengene Corporation
Target Recruit Count
84
Registration Number
NCT05265975
Locations
🇨🇳

The Second Affiliated Hospital of PLA Army Medical University, Chongqing, Chongqing, China

🇨🇳

Wuhan Union Hospital, Wuhan, Hubei, China

🇨🇳

The first Affiliated Hospital of China medical University, Shenyang, Liaoning, China

and more 3 locations

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

First Posted Date
2022-01-21
Last Posted Date
2022-05-24
Lead Sponsor
Chunrui Li
Target Recruit Count
20
Registration Number
NCT05201118
Locations
🇨🇳

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hu Bei, China

Selinexor Combination Ph 1 Study

Phase 1
Withdrawn
Conditions
Solid Tumor Malignancy
Interventions
Drug: Selinexor
Drug: Irinotecan
First Posted Date
2022-01-04
Last Posted Date
2022-01-04
Lead Sponsor
Martin Gutierrez
Registration Number
NCT05177276
Locations
🇺🇸

John Theurer Cancer Center at HackensackUMC, Hackensack, New Jersey, United States

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

First Posted Date
2021-10-29
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
210
Registration Number
NCT05099003
Locations
🇺🇸

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 115 locations

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

First Posted Date
2021-09-05
Last Posted Date
2024-05-17
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
63
Registration Number
NCT05035745
Locations
🇸🇬

National University Hospital, Singapore, Singapore

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

First Posted Date
2021-08-31
Last Posted Date
2024-10-26
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
222
Registration Number
NCT05028348
Locations
🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

California Cancer Associates for Research and Excellence, Encinitas, California, United States

🇺🇸

University of California, San Francisco, Fresno, California, United States

and more 91 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy